The Food and Drug Administration granted accelerated approval for Adaptimmune Therapeutics’ cell therapy Tecelra in treating a specific form of cancer. The drug is on track to treat patients with ...

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - ...

Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind treatment for a rare type of cancer in the soft tissues that most often affects young ...

Revenue Guidance: Full-year Tecelra sales projected between $35 million and $45 million. Net Sales for Q1 2025: $4 million from Tecelra treatments. Tecelra Treatments Invoiced: 14 treatments in 2025 ...

Regulatory action marks the first engineered cell therapy approved for a solid tumor cancer in the United States. The FDA has granted accelerated approval to Adaptimmune Therapeutics’ Tecelra ...

Management projected "revenue guidance for the full year of between $35 million and $45 million in TECELRA sales." Rawcliffe described the sales range as "roughly, approximately between 50 and 70 ...

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Several Authorized Treatment Centers (ATCs) are accepting referrals across ...

Adaptimmune Therapeutics’ Tecelra (afamitresgene autoleucel) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat certain cases of synovial sarcoma. The ...

TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that ...